Works matching IS 00126667 AND DT 2022 AND VI 82 AND IP 15
Results: 6
Correction to: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy.
- Published in:
- Drugs, 2022, v. 82, n. 15, p. 1541, doi. 10.1007/s40265-022-01794-0
- By:
- Publication type:
- Article
Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids.
- Published in:
- Drugs, 2022, v. 82, n. 15, p. 1549, doi. 10.1007/s40265-022-01790-4
- By:
- Publication type:
- Article
Pucotenlimab: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 15, p. 1557, doi. 10.1007/s40265-022-01787-z
- By:
- Publication type:
- Article
Novel Drug Therapeutics in Celiac Disease: A Pipeline Review.
- Published in:
- Drugs, 2022, v. 82, n. 15, p. 1515, doi. 10.1007/s40265-022-01784-2
- By:
- Publication type:
- Article
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
- Published in:
- Drugs, 2022, v. 82, n. 15, p. 1527, doi. 10.1007/s40265-022-01797-x
- By:
- Publication type:
- Article